Status:
COMPLETED
Enoxaparin Versus Unfractionated Heparin in PCI
Lead Sponsor:
Triemli Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI
Eligibility Criteria
Inclusion
- PCI for stable ischemia or ACS
Exclusion
- Cardiogenic shock,
- Pretreatment with study drugs,
- Lack of informed consent
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
2100 Patients enrolled
Trial Details
Trial ID
NCT00439855
Start Date
September 1 2003
End Date
February 1 2006
Last Update
February 26 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Cardiology Triemli Hospital Zurich
Zurich, Switzerland, 8063